000			01201 a2200325 4500
005			20250511194006.0
264		0	_c19920717
008			199207s 0 0 eng d
022			_a0114-5916
024	7		_a10.2165/00002018-199207020-00001 _2doi
040			_aNLM _beng _cNLM
100	1		_aMitchell, A A
245	0	0	_aOral retinoids. What should the prescriber known about their teratogenic hazards among women of child-bearing potential? _h[electronic resource]
260			_bDrug safety _c
300			_a79-85 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
650	0	4	_aAbnormalities, Drug-Induced _xepidemiology
650	0	4	_aAdult
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInfant, Newborn
650	0	4	_aIsotretinoin _xadverse effects
650	0	4	_aPregnancy
650	0	4	_aRetinoids _xadverse effects
650	0	4	_aTeratogens
650	0	4	_aUnited States _xepidemiology
650	0	4	_aVitamin A _xadverse effects
773	0		_tDrug safety _gvol. 7 _gno. 2 _gp. 79-85
856	4	0	_uhttps://doi.org/10.2165/00002018-199207020-00001 _zAvailable from publisher's website
999			_c1612398 _d1612398